



COMPANY OVERVIEW

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

RECENT NEWS

Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International

Feb 6 2020, 8:11 AM EST

Amarantus Releases Letter to Shareholders

Feb 4 2020, 9:54 AM EST

Amarantus Acquires Majority Interest in CBD Wellness Company Hempori

Jan 30 2020, 9:05 AM EST

STOCK OVERVIEW

Symbol	AMBS
Exchange	OTCPink
Shares OS	68,272,000
Market Cap	\$764646
Last Price	\$0.0112
52-Week Range	\$0.0045 - \$0.0235
Fiscal Year End	December 31

09/28/2020 02:53 PM
EDT

INVESTOR RELATIONS

American Capital Ventures, Inc.
Howard Gostfrand
President
T: 305-918-7000
F: 305-468-6165
hg@amcapventures.com

MANAGEMENT TEAM

Gerald E. Commissiong

President & Chief Executive Officer

Brian E. Harvey, MD, PhD

Chief Regulatory Advisor

Elise Brownell, Ph.D.

Senior Vice President of Operations and Project Management

John W. Commissiong, PhD

Chief Scientific Officer

Paula Trzepacz, MD

Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics

Dr. Richard Kagan

Chief Medical Advisor to Cutanogen Corporation

AMARANTUS BIOSCIENCE HOLDINGS, INC.

45 Wall Street
Suite 920
New York, NY 10005
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.